Respiratory
Boehringer Ingelheim has over 90 years of heritage in managing respiratory disease. Our focus is on improving the quality of life of patients suffering from debilitating respiratory diseases and enabling them to maintain a more independent life
INTRODUCTION
Respiratory
Boehringer Ingelheim has emerged as a leader in this disease area, having launched several treatments in a range of respiratory conditions including asthma, chronic obstructive pulmonary disease (COPD), SSc ILD and PF ILD. COPD is a serious, progressive lung disease that limits airflow in the lungs. COPD is preventable and treatable but not curable and by 2033 it is predicted to be the third leading cause of death worldwide.1 An important goal in the management of COPD is increaseing a patient's ability to live their life to the extent they love to and keep active for longer.
1What is chronic obstructive pulmonary disease (COPD)? World Health Organisation.2013. http://www.who.int/features/qa/48/en/ (accessed August 2018)
Related Content
4:45
PC-SA-102509 Respiratory - Specialty OFEV
1:11
The Threat of Pulmonary Fibrosis Across A range of ILDs
7:19
PC-SA-102502 Respiratory - Specialty OFEV
How to recognize ILD and PPF in patients with CTD
3:43
Treatment of patients with PPF and CTD-ILD
How to understand and manage limited cutaneous SSc-ILD
